Members of GBMA adhere to a high standard of behaviour and this is formalised via their compliance with the Generics and Biosimilar Medicines Association Code of Practice (Code) introduced 1 March 2010.
In accordance with Code requirements a review of the Code was finalised in December 2020 and the 5th edition of the Code came into effect in June 2021.
The GBMA Code of Practice is principle based, providing guidance in a single document, on the different legislation, regulation and guidelines with which sponsors of generic medicines listed on the Australian Register of Therapeutic Goods (ARTG) comply.
The GBMA seeks to use all reasonable endeavours to provide healthcare professionals and consumers with a quick, effective and cost free method for redress of potential complaints against a member with regard to breaches of the Code.
Complaints from stakeholders should, in the first instance, be referred back to the respective member who will use all reasonable endeavours to resolve the complaint quickly and effectively. If the stakeholder is not satisfied with the action or decision of the member, the stakeholder may refer the complaint to the GBMA Code Complaint Committee via the GBMA secretariat electronically to firstname.lastname@example.org or by mail to PO Box 130, North Sydney, NSW 2059.
For detailed information on the Code of Practice, please refer to the Code document posted below.
GBMA welcomes and encourages feedback from stakeholders. Feedback can be submitted electronically to email@example.com or by mail to PO Box 130, North Sydney, NSW 2059.